 Home > Medical News > Latest Medical News > Haisco HSK29116 obtained clinical approval in bulk

Haisco HSK29116 obtained clinical approval in bulk

 Last Update: 2021-04-24
 Source: Internet
 Author: User

Tags

vortioxetine side effects

fluorouracil side effects

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On April 6, Haisco issued an announcement stating that its wholly-owned subsidiary Sichuan Haisco Pharmaceutical Co.

HSK29116 is a class 1 innovative chemical drug developed by Haisco.

At present, BTK small molecule inhibitors have been successfully applied to the treatment of B-cell lymphoma, but the existing marketed BTK inhibitors mainly produce enzyme inhibition by forming a covalent bond with the cysteine residues in the active site of BTK, which has great side effects.

HSK29116 is the first oral BTK-Protac small-molecule anti-tumor drug that was screened based on the Hisco Protac R&D platform.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.